Related Experiment Videos
Summary
Congenital cytomegalovirus (CMV) disease remains a significant public health challenge. Active vaccine development includes live attenuated, glycoprotein B, combined, and DNA plasmid vaccines to prevent CMV infection.
Area of Science:
- Virology
- Immunology
- Vaccinology
- Public Health
Background:
- Congenital cytomegalovirus (CMV) disease is a major, unsolved public health issue.
- Lack of awareness and delayed diagnosis of postnatal abnormalities hinder progress.
- Immune prophylaxis, particularly vaccination, is crucial for resolution.
Purpose of the Study:
- To review the current landscape of cytomegalovirus vaccine development.
- To highlight ongoing research and novel approaches in CMV vaccine strategies.
Main Methods:
- Review of ongoing research in CMV vaccine development.
- Discussion of various vaccine platforms, including live attenuated, subunit, recombinant viral vectors, and DNA vaccines.
- Examination of clinical trial progress for CMV vaccines.
Main Results:
- Multiple CMV vaccine candidates are under active investigation.
- A live attenuated vaccine has undergone extensive study, with potential for genetic improvement.
- A glycoprotein B (gB) vaccine is in clinical trials to assess antibody-mediated protection.
- Investigational approaches include combined vaccines (canarypox recombinant) for cellular and humoral immunity and DNA plasmid vaccines.
Conclusions:
- Cytomegalovirus vaccine development is progressing across diverse platforms.
- Multiple strategies, including live attenuated, gB, combined, and DNA vaccines, show promise.
- Continued research and clinical trials are essential to achieve effective immune prophylaxis against congenital CMV disease.